UKI2S takes 11.2% stake in Camgene Therapeutics Limited, RNA therapeutics firm

Published

UKI2S: largest new Series A stake.

Longriver: 9.7% Series A stake.

Hextwo Capital Inc.: 9.0% Series A stake.

MNL Nominees Ltd for EOS Innovation Fund: next-largest Series A stake.

University: 3.7% Series A stake.

UCEF X/MNL (Parkwalk) nominee: equal Series A stake.

X8 Lund Life Sciences Fund LP: smaller Series A stake.

EOS BBI (KCP) nominee for British Business Investments: smallest Series A stake.

New non-individual holders joined; O2H Nominees has more shares after subdivision.

Filed 2 September 2026, covering multi-year changes from 6 June 2024 to 6 June 2026.

Shareholder data

Source: Companies House confirmation statement (CS01) — period to , filed .

Changes in this confirmation statement

TypeShareholderSharesChangeShare classes
ExitedO2H NOMINEES LIMITED (ON BEHALF OF O2H VENTURES LIMITED)3,200
ORDINARY 3,200
New shareholderO2H NOMINEES LIMITED352,786
ORDINARY 320,000
SERIES A 32,786
New shareholderHEXTWO CAPITAL INC.206,896
SERIES A 206,896
New shareholderMNL NOMINEES LTD (AS NOMINEE FOR&ON BEHALF OF EOS INNOVATION FUND)183,298
SERIES A 183,298
New shareholderAS FUND MNGR OF UCEF X (WITH SHARES TO BE HELD BY MNL(PARKWALK) NOMINESS LTD86,206
SERIES A 86,206
New shareholderUNIVERSITY86,206
SERIES A 86,206
New shareholderX8 LUND LIFE SCIENCES FUND LP68,965
SERIES A 68,965
New shareholderEOS BBI(KCP NOMINEES)LTD AS NOMINE FOR & ON BEHALF BRITISH BUSINESS INVESTMENTS LTD62,696
SERIES A 62,696

Current shareholders (7)

ShareholderTotal sharesShare classes
O2H NOMINEES LIMITED352,786
ORDINARY 320,000
SERIES A 32,786
HEXTWO CAPITAL INC.206,896
SERIES A 206,896
MNL NOMINEES LTD (AS NOMINEE FOR&ON BEHALF OF EOS INNOVATION FUND)183,298
SERIES A 183,298
UNIVERSITY86,206
SERIES A 86,206
AS FUND MNGR OF UCEF X (WITH SHARES TO BE HELD BY MNL(PARKWALK) NOMINESS LTD86,206
SERIES A 86,206
X8 LUND LIFE SCIENCES FUND LP68,965
SERIES A 68,965
EOS BBI(KCP NOMINEES)LTD AS NOMINE FOR & ON BEHALF BRITISH BUSINESS INVESTMENTS LTD62,696
SERIES A 62,696

Share this

Contact the editorial team at editorial@fundingspotter.com